Published in Microvasc Res on September 04, 2008
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer | NCT02018523
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci U S A (2013) 1.55
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica (2010) 1.49
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J (2013) 1.09
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res (2010) 1.05
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J (2013) 1.01
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol (2010) 1.00
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica (2009) 0.97
Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol (2011) 0.95
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother (2014) 0.94
Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol (2013) 0.92
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther (2013) 0.91
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood (2011) 0.90
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 0.90
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia (2011) 0.90
Angiogenesis and progression in human melanoma. Dermatol Res Pract (2010) 0.88
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) (2013) 0.88
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia (2014) 0.87
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol (2011) 0.86
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol (2013) 0.85
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. J Oncol (2010) 0.84
Thalidomide and its analogues in the treatment of Multiple Myeloma. Exp Hematol Oncol (2012) 0.83
Rule-based multi-scale simulation for drug effect pathway analysis. BMC Med Inform Decis Mak (2013) 0.82
mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience (2015) 0.81
Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS One (2012) 0.81
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J (2012) 0.80
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Cancer Gene Ther (2015) 0.80
Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol (2012) 0.76
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med (2016) 0.76
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. Proc Natl Acad Sci U S A (2013) 0.76
Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer. Cancers (Basel) (2011) 0.75
Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity. J Hepatol (2016) 0.75
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. J Med Case Rep (2014) 0.75
Population pharmacokinetics of pomalidomide. J Clin Pharmacol (2015) 0.75
Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer. Gastroenterology Res (2008) 0.75
Electrospun PELCL membranes loaded with QK peptide for enhancement of vascular endothelial cell growth. J Mater Sci Mater Med (2016) 0.75
Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 10.61
Data sharing by scientists: practices and perceptions. PLoS One (2011) 6.48
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res (2008) 2.79
Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity (2007) 2.71
Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res (2003) 2.61
Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res (2008) 2.45
The effect of matrix density on the regulation of 3-D capillary morphogenesis. Biophys J (2007) 2.37
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol (2013) 2.33
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2008) 2.21
Changes in smoking behavior and subsequent mortality risk during a 35-year follow-up of a cohort in Xi'an, China. Am J Epidemiol (2014) 2.16
Diffusion limits of an in vitro thick prevascularized tissue. Tissue Eng (2005) 2.15
Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng Part A (2009) 2.14
Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res (2002) 2.10
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol (2011) 2.00
Mesenchymal stem cells enhance angiogenesis in mechanically viable prevascularized tissues via early matrix metalloproteinase upregulation. Tissue Eng (2006) 1.98
Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J (2005) 1.92
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol (2002) 1.90
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate (2002) 1.86
TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood (2008) 1.83
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood (2004) 1.82
Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts. Tissue Eng Part A (2010) 1.79
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res (2009) 1.79
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res (2007) 1.74
An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol (2008) 1.73
The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. Mol Biol Cell (2011) 1.70
Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother (2006) 1.69
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther (2003) 1.66
Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem (2002) 1.60
Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res (2008) 1.58
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol (2009) 1.57
In vitro perfused human capillary networks. Tissue Eng Part C Methods (2013) 1.57
3D in vivo optical coherence tomography based on a low-voltage, large-scan-range 2D MEMS mirror. Opt Express (2010) 1.55
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res (2005) 1.52
Intake of high sucrose during pregnancy altered large-conductance Ca2+-activated K+ channels and vessel tone in offspring's mesenteric arteries. Hypertens Res (2012) 1.48
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol (2002) 1.35
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2006) 1.34
Optimized fibrin gel bead assay for the study of angiogenesis. J Vis Exp (2007) 1.32
Effects of long-term low-dose cadmium exposure on genomic DNA methylation in human embryo lung fibroblast cells. Toxicology (2007) 1.31
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol (2012) 1.29
Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol (2007) 1.22
Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: involvement of the wnt/glycogen synthase kinase-3 beta pathway. J Immunol (2002) 1.22
Full range physiological mass transport control in 3D tissue cultures. Lab Chip (2012) 1.18
Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem (2009) 1.18
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res (2006) 1.17
Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J Cancer Res Clin Oncol (2012) 1.16
Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res (2002) 1.14
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun (2012) 1.13
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother (2010) 1.13
Macrophages and angiogenesis: a role for Wnt signaling. Vasc Cell (2012) 1.12
Ion-channel assay technologies: quo vadis? Drug Discov Today (2001) 1.12
Suppression of the vacuolar invertase gene prevents cold-induced sweetening in potato. Plant Physiol (2010) 1.11
TNF induction of jagged-1 in endothelial cells is NFkappaB-dependent. Gene (2009) 1.11
Integrated microfluidic chip for endothelial cells culture and analysis exposed to a pulsatile and oscillatory shear stress. Lab Chip (2009) 1.07
Drug-eluting balloon for instent restenosis. Heart (2013) 1.07
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol (2013) 1.07
Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol (2004) 1.06
VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest (2003) 1.05
Increasing Prevalence of Metabolic Syndrome in a Chinese Elderly Population: 2001-2010. PLoS One (2013) 1.04
A microfluidic platform for generating large-scale nearly identical human microphysiological vascularized tissue arrays. Lab Chip (2013) 1.04
Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol (2004) 1.04
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res (2006) 1.03
Photoacoustic imaging based on MEMS mirror scanning. Biomed Opt Express (2010) 1.03
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med (2007) 1.02
A three-dimensional in vitro model of tumor cell intravasation. Integr Biol (Camb) (2014) 1.01
Genetic variants in TGF-β pathway are associated with ovarian cancer risk. PLoS One (2011) 1.01
Down-regulation of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human gastric cancer cells. PLoS One (2012) 1.00
Macrophages participate in IL-17-mediated inflammation. Eur J Immunol (2012) 1.00
Secondhand smoke exposure predicted COPD and other tobacco-related mortality in a 17-year cohort study in China. Chest (2012) 0.99
Isolation of human umbilical vein endothelial cells (HUVEC). J Vis Exp (2007) 0.98
The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. J Clin Neurosci (2012) 0.98
Agrobacterium-mediated transient gene expression and silencing: a rapid tool for functional gene assay in potato. PLoS One (2009) 0.97
HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes. Biochem Biophys Res Commun (2006) 0.97
Antioxidant properties and neuroprotective effects of isocampneoside II on hydrogen peroxide-induced oxidative injury in PC12 cells. Food Chem Toxicol (2013) 0.97
Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PLoS One (2009) 0.95
Clusters of circulating Neisseria gonorrhoeae strains and association with antimicrobial resistance in Shanghai. J Antimicrob Chemother (2008) 0.95
Evaluation of breast tumor margins in vivo with intraoperative photoacoustic imaging. Opt Express (2012) 0.95
BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. Angiogenesis (2012) 0.95
Longitudinal in vivo imaging to assess blood flow and oxygenation in implantable engineered tissues. Tissue Eng Part C Methods (2012) 0.95
Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy. Radiology (2012) 0.93
Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. Int Immunol (2005) 0.93